Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.

2021-03

Tiong, Ing S

Dillon, Richard

Ivey, Adam

Teh, Tse-Chieh

Nguyen, Phillip

Cummings, Nicholas

Taussig, David C

Latif, Annie-Louise

Potter, Nicola E

Runglall, Manohursingh

Russell, Nigel H

Raj, Kavita

Schwarer, Anthony P

Fong, Chun Yew

Grigg, Andrew P

Wei, Andrew H

AML

MRD

NPM1

venetoclax

Journal Article

0000-0001-7417-4343

0000-0001-9333-5296

10.1111/bjh.16722

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD- ) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD.

link

British Journal of Haematology 2021; 192(6): 1026-1030

British Journal of Haematology